Skip Navigation
Find a Doctor


Search for
other physicians or researchers.

Find a Doctor
Photo of Dr. Steven Gore

Steven David Gore, MD

Appointment Phone


Primary Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center


Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphoblastic Leukemia, Chronic Myeloid Leukemia, General Internal Medicine, Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

Research Interests

Drug development in myeloid malignancies; clinical applications of epigenetics


  • English

Clinical Trial Keywords

  • acute myeloid leukemia
  • acute promyelocytic leukemia
  • myelodysplastic syndrome

Additional Resources

Additional Resources +
  • Education +


    • Yale University School of Medicine (New Haven CT) (1984)


    • University of Chicago/ Internal Medicine (Chicago IL) (1987)


    • The Johns Hopkins Hospital/ Oncology (Baltimore MD) (1990)


    • Medical Oncology, American Board of Internal Medicine (1989)
    • Internal Medicine, American Board of Internal Medicine (1987)
  • Research & Publications +

    Selected Publications

    Cheson, B.D.; Greenberg, P.L.; Bennett, J.M.; Lowenberg, B.; Wijermans, P.W.; Nimer, S.D.; Pinto, A.; Beran, M.; de Witte, T.M.; Stone, R.M.; Mittelman, M.; Sanz, G.F.; Gore, S.D.; Schiffer, C.A.; Kantarjian, H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-425.

    Deeg, H.J.; Bowen, D.; Gore, S.D.; Haferlach, T.; Beau, M.M.; Niemeyer, C. Myelodysplastic Syndrome. New York, NY: Springer; 2006.

    Gore, S.D. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. J Natl Compr Canc Netw. 2006 Jan;4(1):83-90.

    Gore, S.D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C.B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J.E.; Rudek, M.A.; Zhao, M.; Smith, B.D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; Murgo, A.; Weng, L.J.; Herman, J.G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006 Jun 15;66(12):6361-6369.
    Gore, S.D.; Jones, C.; Kirkpatrick, P. Decitabine. Nat Rev Drug Discov. 2006 Nov;5(11):891-892.

    Greenberg, P.L.; Baer, M.R.; Bennett, J.M.; Bloomfield, C.D.; De Castro, C.M.; Deeg, H.J.; Devetten, M.P.; Emanuel, P.D.; Erba, H.P.; Estey, E.; Foran, J.; Gore, S.D.; Millenson, M.; Navarro, W.H.; Nimer, S.D.; O''Donnell, M.R.; Saba, H.I.; Spiers, K.; Stone, R.M.; Tallman, M.S. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan;4(1):58-77.

    Bagatell, R.; Gore, L.; Egorin, M.J.; Ho, R.; Heller, G.; Boucher, N.; Zuhowski, E.G.; Whitlock, J.A.; Hunger, S.P.; Narendran, A.; Katzenstein, H.M.; Arceci, R.J.; Boklan, J.; Herzog, C.E.; Whitesell, L.; Ivy, S.P.; Trippett, T.M. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res. 2007 Mar 15;13(6):1783-1788.

    Carraway, H.E.; Gore, S.D. Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol. 2007 May 20;25(15):1955-1956.

    Fandy, T.E.; Carraway, H.; Gore, S.D. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 2007 Jan-Feb;13(1):40-48.

    Fandy, T.E.; Ross, D.D.; Gore, S.D.; Srivastava, R.K. Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL. Cancer Chemother Pharmacol. 2007 Aug;60(3):313-319.

    Gojo, I.; Jiemjit, A.; Trepel, J.B.; Sparreboom, A.; Figg, W.D.; Rollins, S.; Tidwell, M.L.; Greer, J.; Chung, E.J.; Lee, M.J.; Gore, S.D.; Sausville, E.A.; Zwiebel, J.; Karp, J.E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007 Apr 1;109(7):2781-2790.

    Gore, S.D. Intravenous azacitidine for MDS. Clin Adv Hematol Oncol. 2007 Mar;5(3):234.

    Karp, J.E.; Ricklis, R.M.; Balakrishnan, K.; Briel, J.; Greer, J.; Gore, S.D.; Smith, B.D.; McDevitt, M.A.; Carraway, H.; Levis, M.J.; Gandhi, V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15;110(6):1762-1769.

    Karp, J.E.; Smith, B.D.; Levis, M.J.; Gore, S.D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R.J.; Wright, J.J.; Colevas, A.D. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-4473.

    Gore, S.D.; Baylin, S.B.; Herman, J.G. Histone Deacetylase Inhibitors and Demethylating Agents. In: Vincent T. DeVita, J.; Lawrence, T.S.; Rosenberg, S.A., editors. 8e ed. Vol. 8e, Section 11, DeVita, Hellman and Rosenberg''s Cancer: Principles & Practice of Oncology, 8e. York, PA: Lippincott Williams and Wilkins; 2008.

    Gore, S.D.; Hermes-DeSantis, E.R. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control. 2008 Oct;15 Suppl:40-49.

    Gorelik, B.; Ziv, I.; Shohat, R.; Wick, M.; Hankins, W.D.; Sidransky, D.; Agur, Z. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res. 2008 Nov 1;68(21):9033-9040.

    Griffiths, E.A.; Gore, S.D. DNA methyltransferase inhibitors: class effect or unique agents? Leuk Lymphoma. 2008 Apr;49(4):650-651.

    Griffiths, E.A.; Gore, S.D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in hematology. 2008 Jan;45(1):23-30.

    Jiemjit, A.; Fandy, T.E.; Carraway, H.; Bailey, K.A.; Baylin, S.; Herman, J.G.; Gore, S.D. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene. 2008 Jun 5;27(25):3615-3623.

    Karp, J.E.; Smith, B.D.; Gojo, I.; Lancet, J.E.; Greer, J.; Klein, M.; Morris, L.; Levis, M.J.; Gore, S.D.; Wright, J.J.; Garrett-Mayer, E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15;14(10):3077-3082.

    Fandy, T.E.; Herman, J.G.; Kerns, P.; Jiemjit, A.; Sugar, E.A.; Choi, S.H.; Yang, A.S.; Aucott, T.; Dauses, T.; Odchimar-Reissig, R.; Licht, J.; McConnell, M.J.; Nasrallah, C.; Kim, M.K.; Zhang, W.; Sun, Y.; Murgo, A.; Espinoza-Delgado, I.; Oteiza, K.; Owoeye, I.; Silverman, L.R.; Gore, S.D.; Carraway, H.E. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009 Sep 24;114(13):2764-2773.

    Griffiths, E.A.; Gore, S.D. MicroRNA: mIR-ly regulators of DNMT? Blood. 2009 Jun 18;113(25):6269-6270.

    Karp, J.E.; Flatten, K.; Feldman, E.J.; Greer, J.M.; Loegering, D.A.; Ricklis, R.M.; Morris, L.E.; Ritchie, E.; Smith, B.D.; Ironside, V.; Talbott, T.; Roboz, G.; Le, S.B.; Meng, X.W.; Schneider, P.A.; Dai, N.T.; Adjei, A.A.; Gore, S.D.; Levis, M.J.; Wright, J.J.; Garrett-Mayer, E.; Kaufmann, S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14;113(20):4841-4852.

    Lin, J.; Gilbert, J.; Rudek, M.A.; Zwiebel, J.A.; Gore, S.; Jiemjit, A.; Zhao, M.; Baker, S.D.; Ambinder, R.F.; Herman, J.G.; Donehower, R.C.; Carducci, M.A. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6241-6249.

    Ye, Y.; McDevitt, M.A.; Guo, M.; Zhang, W.; Galm, O.; Gore, S.D.; Karp, J.E.; Maciejewski, J.P.; Kowalski, J.; Tsai, H.L.; Gondek, L.P.; Tsai, H.C.; Wang, X.; Hooker, C.; Smith, B.D.; Carraway, H.E.; Herman, J.G. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res. 2009 Nov 1;69(21):8482-8490.

    Bolanos-Meade, J.; Smith, B.D.; Gore, S.D.; McDevitt, M.A.; Luznik, L.; Fuchs, E.J.; Jones, R.J. 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2010 Oct 15;In Press.
    Emadi, A.; Gore, S.D. Arsenic trioxide - An old drug rediscovered. Blood Rev. 2010 Jul-Sep;24(4-5):191-199.

    Gore, S.D.; Gojo, I.; Sekeres, M.A.; Morris, L.; Devetten, M.; Jamieson, K.; Redner, R.L.; Arceci, R.; Owoeye, I.; Dauses, T.; Schachter-Tokarz, E.; Gallagher, R.E. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010 Feb 20;28(6):1047-1053.

    Griffiths, E.A.; Gore, S.D.; Hooker, C.; McDevitt, M.A.; Karp, J.E.; Smith, B.D.; Mohammad, H.P.; Ye, Y.; Herman, J.G.; Carraway, H.E. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 2010 Sep;51(9):1711-1719

    Griffiths, E.A.; Gore, S.D.; Hooker, C.M.; Mohammad, H.P.; McDevitt, M.A.; Smith, B.D.; Karp, J.E.; Herman, J.G.; Carraway, H.E. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010 Oct 3;5(7 ).

    Karp, J.E.; Blackford, A.; Smith, B.D.; Alino, K.; Seung, A.H.; Bolanos-Meade, J.; Greer, J.M.; Carraway, H.E.; Gore, S.D.; Jones, R.J.; Levis, M.J.; McDevitt, M.A.; Doyle, L.A.; Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul;34(7):877-882.

    Kasamon, Y.L.; Jones, R.J.; Gocke, C.D.; Blackford, A.L.; Seifter, E.J.; Davis-Sproul, J.M.; Gore, S.D.; Ambinder, R.F. Extended Follow-Up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin''s Lymphomas. Biol Blood Marrow Transplant. 2010 Jul 21.

    Loaiza-Bonilla, A.; Gore, S.D.; Carraway, H.E. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. Curr Opin Hematol. 2010 Mar;17(2):104-109.

    Pratz, K.W.; Cho, E.; Levis, M.J.; Karp, J.E.; Gore, S.D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S.D.; Carducci, M.A.; Wright, J.J.; Rudek, M.A.; Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010 Aug;24(8):1437-1444.

    Thomas, M.B.; Jaffe, D.; Choti, M.M.; Belghiti, J.; Curley, S.; Fong, Y.; Gores, G.; Kerlan, R.; Merle, P.; O''Neil, B.; Poon, R.; Schwartz, L.; Tepper, J.; Yao, F.; Haller, D.; Mooney, M.; Venook, A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010 Sep 1;28(25):3994-4005.

    Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Jan 14;Epub 1/18/11.

    Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Upcoming Events +
  • Contact & Locations +


    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-955-8781
    Appointment Phone: 410-955-8964
    Fax: 410-614-1005
    Location Map


    • Oncology

Is This You? Edit Profile


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer